Unfortunately, many pharmaceutical companies have excluded development of AhR ligands from their pipelines [32] due to concerns that CYP1A1 induction will increase cancer risk or otherwise induce “TCDD-like toxicity”. The gene discussed is CYP1A1; the disease is cancer.